Latest Funding News

Ora Banda Mining has reported significant new high-grade gold intercepts from drilling at its Sand King northern corridor, pointing to a potential expansion of its mining inventory and extended mine life.

Lefroy Exploration has received a second $0.75 million cash advance from BML Ventures, reinforcing its funding position ahead of key production milestones at the Lucky Strike Gold Project.

Netwealth Group Limited will compensate members affected by the First Guardian Master Fund collapse with $101 million, impacting its 1H26 profit but aiming to restore member confidence swiftly.

Equus Energy Limited launches a $15 million public offer to fund the acquisition and development of the Equus Gas Project in Western Australia, backed by conditional funding from Alcoa. The project boasts a large independently certified contingent gas resource, positioning the company to address looming supply shortfalls in domestic and LNG markets.

ActivEX Limited has raised $100,000 through a strategic share placement to Business Victor Investments, aiming to accelerate its exploration projects and strengthen working capital.

Hawsons Iron Ltd has declared a JORC-compliant Probable Ore Reserve of 2.3 billion tonnes and completed a positive Pre-Feasibility Study supporting a 26-year, 12Mtpa magnetite concentrate project in New South Wales.

Torque Metals has raised $16.2 million through a $15 million placement and early option exercises, setting the stage for an aggressive drilling campaign at its Paris Gold Project in Western Australia.

Anatara Lifesciences reports encouraging pre-clinical results for its anti-obesity candidate AOC, demonstrating significant reductions in weight regain and visceral fat in mice. However, a delay in mechanism of action studies pushes full data release to January 2026.

Truscott Mining Corporation has initiated a $1.44 million capital raise through a share placement accompanied by unlisted options, aiming to bolster its exploration and development efforts.

Opthea Limited has announced a strategic pivot to develop OPT-302 for Lymphangioleiomyomatosis (LAM), a rare lung disease affecting women, aiming for ASX reinstatement in 2026. The company leverages strong intellectual property and cash reserves to pursue orphan drug designation and clinical development.

Humm Group has received a shareholder notice to remove key directors alongside a non-binding acquisition proposal from Credit Corp, signaling potential major changes ahead.

Neurotech International has locked in $4 million through a share placement to advance its promising paediatric neurological drug, NTI164. The raise, supported by both new and existing investors including company directors, aims to fund critical clinical and regulatory milestones.